2 results
Approved WMOCompleted
To assess safety, tolerability and pharmacokinetics of a single subcutaneous administration of HPV-NIRD1.
Approved WMORecruiting
To investigate whether mifepristone (7-day, 1200 mg/day) added to treatment as usual (TAU), is more efficacious than placebo in reducing depressive symptom severity (Inventory of Depressive Symptoms-Self Rated questionnaire; IDS-SR) in patients with…